Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 176

1.

Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells.

Markovina S, Callander NS, O'Connor SL, Kim J, Werndli JE, Raschko M, Leith CP, Kahl BS, Kim K, Miyamoto S.

Mol Cancer Res. 2008 Aug;6(8):1356-64. doi: 10.1158/1541-7786.MCR-08-0108.

2.

Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-kappaB activity in myeloma cells.

Markovina S, Callander NS, O'Connor SL, Xu G, Shi Y, Leith CP, Kim K, Trivedi P, Kim J, Hematti P, Miyamoto S.

Mol Cancer. 2010 Jul 6;9:176. doi: 10.1186/1476-4598-9-176.

3.

Combination chemotherapy increases cytotoxicity of multiple myeloma cells by modification of nuclear factor (NF)-κB activity.

Salem K, Brown CO, Schibler J, Goel A.

Exp Hematol. 2013 Feb;41(2):209-18. doi: 10.1016/j.exphem.2012.10.002. Epub 2012 Oct 11.

4.

Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma.

Yang DT, Young KH, Kahl BS, Markovina S, Miyamoto S.

Mol Cancer. 2008 May 19;7:40. doi: 10.1186/1476-4598-7-40.

5.

TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.

Sagawa M, Tabayashi T, Kimura Y, Tomikawa T, Nemoto-Anan T, Watanabe R, Tokuhira M, Ri M, Hashimoto Y, Iida S, Kizaki M.

Cancer Sci. 2015 Apr;106(4):438-46. doi: 10.1111/cas.12616. Epub 2015 Mar 10.

6.

[Proteasome inhibitor induces apoptosis and influences the expression of Notch1 and NF-kappaB in multiple myeloma RPMI8226 cells].

Wang H, Liu X, Xu B.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Jun;16(3):531-7. Chinese.

PMID:
18549623
7.

NF-kappa B as a therapeutic target in multiple myeloma.

Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, Munshi N, Dang L, Castro A, Palombella V, Adams J, Anderson KC.

J Biol Chem. 2002 May 10;277(19):16639-47. Epub 2002 Feb 28.

8.

The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance.

Chauhan D, Li G, Podar K, Hideshima T, Shringarpure R, Catley L, Mitsiades C, Munshi N, Tai YT, Suh N, Gribble GW, Honda T, Schlossman R, Richardson P, Sporn MB, Anderson KC.

Blood. 2004 Apr 15;103(8):3158-66. Epub 2003 Dec 11.

9.

The proteasome inhibitor bortezomib reverses P-glycoprotein-mediated leukemia multi-drug resistance through the NF-kappaB pathway.

Wang H, Wang X, Li Y, Liao A, Fu B, Pan H, Liu Z, Yang W.

Pharmazie. 2012 Feb;67(2):187-92.

PMID:
22512091
10.

Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.

Hideshima T, Ikeda H, Chauhan D, Okawa Y, Raje N, Podar K, Mitsiades C, Munshi NC, Richardson PG, Carrasco RD, Anderson KC.

Blood. 2009 Jul 30;114(5):1046-52. doi: 10.1182/blood-2009-01-199604. Epub 2009 May 12.

11.
12.

Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells.

Chauhan D, Li G, Podar K, Hideshima T, Mitsiades C, Schlossman R, Munshi N, Richardson P, Cotter FE, Anderson KC.

Blood. 2004 Oct 15;104(8):2458-66. Epub 2004 Jun 24.

13.

Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro.

Mitsiades CS, McMillin D, Kotoula V, Poulaki V, McMullan C, Negri J, Fanourakis G, Tseleni-Balafouta S, Ain KB, Mitsiades N.

J Clin Endocrinol Metab. 2006 Oct;91(10):4013-21. Epub 2006 Jul 18.

PMID:
16849420
14.

A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.

Chauhan D, Li G, Podar K, Hideshima T, Neri P, He D, Mitsiades N, Richardson P, Chang Y, Schindler J, Carver B, Anderson KC.

Cancer Res. 2005 Sep 15;65(18):8350-8.

15.

Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-kappaB and activator protein-1 related mechanisms.

Chen Z, Ricker JL, Malhotra PS, Nottingham L, Bagain L, Lee TL, Yeh NT, Van Waes C.

Mol Cancer Ther. 2008 Jul;7(7):1949-60. doi: 10.1158/1535-7163.MCT-07-2046.

16.

The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma.

Berenson JR, Ma HM, Vescio R.

Semin Oncol. 2001 Dec;28(6):626-33. Review.

PMID:
11740821
17.

Dual inhibition of canonical and noncanonical NF-κB pathways demonstrates significant antitumor activities in multiple myeloma.

Fabre C, Mimura N, Bobb K, Kong SY, Gorgun G, Cirstea D, Hu Y, Minami J, Ohguchi H, Zhang J, Meshulam J, Carrasco RD, Tai YT, Richardson PG, Hideshima T, Anderson KC.

Clin Cancer Res. 2012 Sep 1;18(17):4669-81. doi: 10.1158/1078-0432.CCR-12-0779. Epub 2012 Jul 17.

19.

PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells.

Bhalla S, Balasubramanian S, David K, Sirisawad M, Buggy J, Mauro L, Prachand S, Miller R, Gordon LI, Evens AM.

Clin Cancer Res. 2009 May 15;15(10):3354-65. doi: 10.1158/1078-0432.CCR-08-2365. Epub 2009 May 5. Erratum in: Clin Cancer Res. 2009 Jul 15;15(14):4784-5.

20.

Bortezomib induces nuclear translocation of IκBα resulting in gene-specific suppression of NF-κB--dependent transcription and induction of apoptosis in CTCL.

Juvekar A, Manna S, Ramaswami S, Chang TP, Vu HY, Ghosh CC, Celiker MY, Vancurova I.

Mol Cancer Res. 2011 Feb;9(2):183-94. doi: 10.1158/1541-7786.MCR-10-0368. Epub 2011 Jan 11.

Supplemental Content

Support Center